Patent ID: 6544988
Filing Date: 2003-04-08
Classification: A61K,A61P,C07D

Abstract:
A method of treating cancer in a mammal in need of such treatment which is comprised of administering to said mammal a therapeutically effective amount of a compound of the formula I: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:X is CH; R1 and R3 are independently selected from the group consisting of: 1) H, 2) C1-10 alkyl, 3) C2-10 alkenyl, 4) C2-10 alkynyl, 5) aryl, 6) halo, 7) OH, and 8) heterocyclyl, said alkyl, alkenyl, alkynyl, aryl, and heterocyclyl is optionally substituted with one to three members selected from Ra; R2 is: 1) H, 2) C1-6 alkyl, 3) aryl, 4) OH, 5) NO2, 6) NH2, or 7) halogen; R5 is: 1) H, 2) C1-6 alkyl, 3) OH, 4) Oâ€”C1-6 alkyl, 5) halo, 6) NH2, or 7) NO2; R7 and R8 are independently selected from the group consisting of: 1) H, 2) C1-10 alkyl, 3) COR, 4) COOR, 5) aryl, and 6) heterocyclyl, said alkyl, aryl and heterocyclyl optionally substituted with R9, or NR7R8 are taken together to form a heterocyclic 5-10 membered saturated or unsaturated ring containing, in addition to the nitrogen atom, one to two additional heteroatoms selected from the group consisting of N, O and S, said ring optionally substituted with one or two substituents selected from Ra; R9 is aryl or heterocyclyl, said aryl and heterocyclyl is optionally substituted with from one to three members selected from Ra; R10 is: 1) H, 2) C1-6 alkyl, 3) aryl, or 4) heterocyclyl, said alkyl, aryl, and heterocyclyl is optionally substituted with one to three members selected from Ra; Ra is: 1) C1-10 alkyl, 2) halogen, 3) NO2, 4) OR, 5) NR7R8, 6) CN, 7) aryl, or 8) heterocyclyl; and R is H or C1-6 alkyl.